Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline
Executive Summary
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.
You may also be interested in...
AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition
AstraZeneca’s recently-acquired Alexion unit is paying $150m upfront to buy the remainder of Caelum Biosciences and its late-stage therapy for light chain amyloidosis, a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys.
Ninlaro Positive In Non-Transplant MM Maintenance
Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.
Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.